Section 04 · Monograph

Ponesimod

Reviewed Nov 2026FDA label

PonvoryS1P receptor modulator

Indications

Treatment of relapsing forms of multiple sclerosis (MS) in adults, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive diseaseFDA-labeled

Ponesimod is a sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity to S1P receptor 1
Blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood
May reduce lymphocyte migration into the CNS, lowering inflammatory demyelinating activity in MS
S1P1 engagement on cardiac pacemaker cells underlies the transient, dose-dependent decrease in heart rate on treatment initiation, mitigated by gradual up-titration
Ponesimod is a functional antagonist rather than a competitive antagonist, causing internalization of S1P1 receptors on lymphocytes

Requires a 14-day dose titration using a starter pack before reaching the maintenance dose
Days 1–2: 2 mg; Days 3–4: 3 mg; Days 5–6: 4 mg; Day 7: 5 mg; Day 8: 6 mg; Day 9: 7 mg; Day 10: 8 mg; Day 11: 9 mg; Days 12–14: 10 mg
Day 15 onward: maintenance dose of 20 mg orally once daily
First-dose cardiac monitoring (4 hours) recommended for patients with sinus bradycardia (HR <55 bpm), first- or second-degree Mobitz type I AV block, or history of MI or heart failure — hourly pulse/BP checks plus ECG before and after observation
If 4 or more consecutive daily doses are missed, treatment must be reinitiated with Day 1 of the titration regimen using a new starter pack

No dose adjustment needed for mild hepatic impairment (Child-Pugh A); not recommended in moderate or severe hepatic impairment (Child-Pugh B/C)

Myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure requiring hospitalization, or Class III/IV heart failure within the last 6 months
Mobitz type II second-degree AV block, third-degree AV block, sick sinus syndrome, or sino-atrial block, unless patient has a functioning pacemaker

Not recommended in patients concurrently treated with QT-prolonging drugs; Class Ia and Class III anti-arrhythmics increase risk of torsades de pointes
Beta-blockers have an additive heart-rate-lowering effect; if resting HR ≤55 bpm, interrupt beta-blocker until baseline HR is >55 bpm before initiating ponesimod, then may resume beta-blocker after titration
Initiating ponesimod after alemtuzumab is not recommended due to prolonged, additive immune effects
Can generally be initiated immediately after stopping beta interferon or glatiramer acetate
Live attenuated vaccines should be avoided during treatment and for 1–2 weeks after discontinuation; vaccination response may be diminished during therapy

Upper respiratory tract infection
Hepatic transaminase elevation
Hypertension
Urinary tract infection
Dyspnea
Dizziness
Cough
Pain in extremity
First-degree AV block/bradycardia (mean Day 1 HR decrease of 6 bpm; no second- or third-degree AV block observed in trials)
Macular edema (1.1% vs 0% with comparator)
Seizures (1.4% vs 0.2% with comparator; causality unclear)

Baseline ECG to assess cardiac conduction before first dose
Baseline complete blood count including lymphocyte count
Baseline and periodic liver function tests (transaminases and bilirubin) — median time to ≥3x ULN elevation was about 3 months in trials
Baseline fundus/macular evaluation, with follow-up if visual symptoms occur, especially in patients with diabetes or uveitis history
Baseline skin examination given increased risk of cutaneous malignancies with S1P modulators
Varicella zoster antibody testing prior to initiation
Blood pressure monitoring during treatment
Monitor for symptoms suggestive of PML and suspend treatment if suspected
Continue monitoring for infection risk for 1–2 weeks after discontinuation due to residual pharmacodynamic effects

Based on animal data, ponesimod may cause fetal harm; animal studies showed limb malformations (syndactyly, ectrodactyly), cardiovascular defects including ventricular septal defects, and post-implantation loss
Women of childbearing potential should use effective contraception during treatment and for 1 week after stopping ponesimod
No human data on presence of ponesimod in breast milk; animal studies detected ponesimod in offspring plasma, suggesting excretion into milk — weigh benefits of breastfeeding against potential infant risk